Discover
SGMT
Sagimet Biosciences Inc.
7.46
2 x 5.69
2 x 9.44
bid
ask
-
0.27
3.49%
2 @ 04:00 PM
7.30 -0.16 (2.14%)
| Ytd | 26.01% | |
| 1y | -7.10% |
7.31
day range
7.95
4.50
52 week range
11.41
| Open | 7.75 | Prev Close | 7.73 | Low | 7.31 | High | 7.95 | Mkt Cap | 460.67M |
| Vol | 1.25M | Avg Vol | 1.80M | EPS | -1.35 | P/E | N/A | Forward P/E | -1.40 |
| Beta | N/A | Short Ratio | 1.37 | Inst. Own | 66.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 7.11 | 200-d Avg | 6.55 | 1yr Est | 29.14 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.47 | -0.45 | 0.02 | 4.26% |
| 2024-08-14 | 2024-06 | -0.34 | -0.25 | 0.09 | 26.47% |
| 2024-08-14 | 2024-06 | -0.34 | N/A | N/A | N/A |
| 2024-05-15 | 2024-03 | -0.41 | N/A | N/A | N/A |
| 2024-05-15 | 2024-03 | -0.41 | -0.23 | 0.18 | 43.90% |
| 2024-03-25 | 2023-12 | -0.57 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-06 | Oppenheimer | Upgrade | Outperform | |
| 2024-11-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-12 | UBS | Upgrade | Buy | |
| 2024-10-31 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-02 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-15 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
Profile
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-03-25 | HAPPEL DAVID | Chief Executive Officer | 639.20K | Purchase |
| 2024-07-22 | KEMBLE GEORGE | Officer and Director | 118.69K | Sale |
| 2023-07-17 | KPCB PBD ASSOCIATES, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-07-18 | MARTINS EDUARDO BRUNO | Officer | 81.21K | Sale |
| 2023-07-17 | NEW ENTERPRISE ASSOCIATES 13, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2023-07-17 | PARSEY MERDAD V | Director | 12.79K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Point72 Asset Management, L.P. | 2.39M | 11.90M | 7.80% |
| 2024-09-29 | NEA Management Company, LLC | 2.00M | 9.94M | 6.52% |
| 2024-09-29 | Blue Owl Capital Holdings LP | 1.67M | 8.32M | 5.46% |
| 2024-09-29 | Baker Bros. Advisors, LP | 1.38M | 6.87M | 4.50% |
| 2024-09-29 | Alyeska Investment Group, L.p. | 1.38M | 6.85M | 4.49% |
| 2024-09-29 | Citadel Advisors Llc | 1.22M | 6.04M | 3.96% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 763.99K | 3.80M | 2.49% |
| 2024-09-29 | BlackRock Health Sciences Term Trust | 408.12K | 2.03M | 1.33% |
| 2024-08-30 | Blackrock Funds-Health Sciences Opportunity Portfolio | 302.93K | 1.51M | 0.99% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 246.11K | 1.22M | 0.80% |
| 2024-09-29 | Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund | 185.00K | 919.45K | 0.60% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 133.43K | 663.14K | 0.43% |